Chemical pleurodesis for malignant pleural effusion: which agent is perfect?

CARDIOTHORACIC SURGEON - Tập 28 Số 1 - 2020
Mohamed Elshabrawy Saleh1, Gehad Awad1, Mohammed Sanad1
1Department of Cardiothoracic Surgery, Faculty of Medicine, Mansoura University, Mansoura, Egypt

Tóm tắt

Abstract Background

Pleurodesis is defined as symphysis between two layers of pleura to prevent recurrence of effusion, and it is the best available treatment for recurrent effusions of incurable malignancies. An ideal agent must be highly effective, safe, inexpensive, and readily available which is yet to be identified.

The aim of this study was to assess our results of medical pleurodesis, using 3 different chemical agents: bleomycin ampoules, doxycycline capsules, povidone–iodine solution, through two different routes, chest tube and small bore indwelling catheter.

Over a period of 5 years, 104 patients with malignant recurrent pleural effusion underwent pleurodesis at our university hospital, using 3 different agents and two routes of delivery.

Results

Fifty patients were male, patients’ age ranged from 22 to 74 years (57.55 ± 9.02). Fifty-nine patients (56.7%) had right-sided effusion, 61 patients (58.7%) had massive effusion. All patients were dyspneic. The rout of effusion drainage and sclerosing agent instillation was chest tube in 64 patients (61.5%) and small indwelling catheter in 40 patients. Forty-three patients received bleomycin, 36 patients received doxycycline, and 25 patients received povidone–iodine. The total success rate was 78.8%.

Conclusion

Pleurodesis is a safe acceptable palliative procedure for malignant pleural effusion with not yet definite ideal agent or rout. Hence, the availability and the expense of agent are important.

Từ khóa


Tài liệu tham khảo

Psallidas I, Kalomenidis I, Porcel JM, Robinson BW, Stathopoulos GT (2016) Malignant pleural effusion: from bench to bedside. European Respiratory Review. 25(140):189–198

Clive AO, Kahan BC, Hooper CE, Bhatnagar R, Morley AJ, Zahan-Evans N, Bintcliffe OJ, Boshuizen RC, Fysh ET, Tobin CL, Medford AR (2014 Dec 1) Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 69(12):1098–1104

Estrada Saló G, Farina Ríos C, Fibla Alfara JJ, Gómez Sebastián G, Unzueta MC, León GC (2003) Spontaneous pneumothorax: Pleurodesis with an iodo-povidone hydroalcoholic solution. Arch Bronconeumol. 39:171–174

Olivares-Torres CA, Laniado-Laborín R, Chávez-García C, León-Gastelum C, Reyes-Escamilla A, Light RW (2002) Iodopovidone pleurodesis for recurrent pleural effusions. Chest. 122:581–583

Pamela B (1994) M. Leigh, A. Steven. Chemical pleurodesis for malignant pleural effusions. Ann. Intern. Med. 120:56–64

World Medical Association. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organ. 2001;79(4):373–374.

Smargiassi A, Inchingolo R, Zanforlin A, Valente S, Soldati G, Corbo GM (2013) Description of free-flowing pleural effusions in medical reports after echographic assessment. Respiration. 85(5):439

Rafei H, Jabak S, Mina A, Tfayli A (2015) Pleurodesis in malignant pleural effusions: Outcome and predictors of success. Integr Cancer Sci Therap. 2:216–221

Davies HE, Lee YG (2013) Management of malignant pleural effusions: questions that need answers. Current opinion in pulmonary medicine. 19(4):374–379

Dey A, Bhuniya S, Datta Chaudhuri A, Pandit S, Saha-Dutta Chowdhury M, Sengupta A, Saha I, De P (2010) Iodopovidone pleurodesis: experience of a tertiary hospital in Kolkata. Singapore Med J. 51(2):163–165

Johnston WW (1985) The malignant pleural effusion: a review of cytopathological diagnoses of 584 specimens from 472 consecutive patients. Cancer. 56:905–909

Elayouty HD, Hassan TM, Alhadad ZA (2012) Povidone- Iodine versus Bleomycin Pleurodesis for Malignant Effusion in Bronchogenic Cancer Guided by Thoracic Echography. J Cancer Sci Ther. 4:182–184

Patz EF, McAdams HP, Erasmus JJ (1998) Sclerotherapy for malignant pleural effusions: a prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage. Chest. 113:1305–1311

Shouman W, Elgazzar A, Hussien R, ElShaaray M (2012) Chemical pleurodesis for malignant pleural effusion. Egyptian Journal of Chest Diseases and Tuberculosis. 61:115–120

Kahrom hadi, Manouchehr Aghajanzadeh, Mohammad Reza Asgari, Mahdi Kahrom Efficacy and safety of povidone-iodine pleurodesis in malignant pleural effusions. 2017;23:53-56

Clementsen P, Evald T, Grode G, Hansen M, Krag JG, Faurschou P (1998) Treatment of malignant pleural effusion: pleurodesis using a small percutaneous catheter. A prospective randomized study. Respir Med. 9(2):593–596

Mager HJ, Maesen B, Verzijlbergen F, Schramel F (2002) Distribution of talc suspension during treatment of malignant pleural effusion with talc pleurodesis. Lung Cancer. 36:77–81

Boland GW, Gazelle GS, Girard MJ (1998) Mueller PR. Asymptomatic hydropneumothorax after therapeutic thoracentesis for malignant pleural effusions Am J Roentgenol. 170:943–946

Clive AO, Jones HE, Bhatnagar R, Preston NJ, Maskell N (2016) Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database of Systematic Reviews. 5